# Curie Capital

> Curie Capital is a VC fund in Netherlands backing Biotechnology and Medical. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Netherlands, United States
- Total investments: 13
- Last investment: Mar 2026
- Lead investor: 8%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/curie-capital-bv/
- Website: https://www.curiecapital.nl/

Curie Capital is a life science focused venture capital firm founded in 2018. It is a new and dynamic investment fund with a personal touch. Curie Capital is based in Amsterdam and invests in early stage companies with talented teams and exciting science and technology. The founding partners Mariette van der Velden and Han de Groot both haveextensive experience in investing, entrepreneurship and managing companies across the full life cycle from startup to (public) exit. The partners leverage their complementary skills and network for the success of their portfolio companies.

## Contacts

5 contacts available for Curie Capital. Shizune tracks 1 team members at Curie Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/curie-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 31% |
| Medical | 3 | 23% |
| Health Care | 3 | 23% |
| Biopharma | 2 | 15% |
| Medical Device | 2 | 15% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 31% |
| Series A | 3 | 23% |
| Series B | 2 | 15% |
| Funding Round | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 6 | 46% |
| United States | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Mariette van der Velden | Managing Partner | 4 | https://shizune.co/investors/profile/mariette-van-der-velden |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M | Seed | Mar 23, 2026 |  |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M | Seed | Dec 03, 2025 |  |
| Avidicure | Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.“AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology. | $50M | Seed | Apr 24, 2025 |  |
| Sirius Medical | Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice forpinpointing tumors | $10.4M |  | Feb 04, 2025 |  |
| Citryll | Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands. | $89.7M | Series B | Dec 09, 2024 |  |
| Flindr Therapeutics | Immagene develops personalized cancer immunotherapies to fight multiple cancer type. | $21.4M | Series A | Apr 24, 2024 |  |
| Sirius Medical | Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice forpinpointing tumors | $12.9M | Series B | Mar 21, 2023 |  |
| Cleara Biotech | Cleara is developing therapeutics to eliminate senescent cells. | $2.5M | Seed | Sep 22, 2022 |  |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $44.2M | Series A | Feb 19, 2022 |  |

10 of 13 investments shown.

## Co-investors
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 5 deals together
- [Holland Capital](https://shizune.co/investors/profile/holland-venture) — VC Fund, 4 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 3 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 3 deals together
- [Oncode Oncology Bridge Fund](https://shizune.co/investors/profile/oncode-oncology-bridge-fund) — VC Fund, 3 deals together
- [ROM Utrecht Region](https://shizune.co/investors/profile/rom-utrecht-region-27bc) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Curie Capital invest in?

Curie Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Curie Capital?

Public channels for Curie Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Curie Capital?

The team at Curie Capital includes Mariette van der Velden (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co